ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Transplantation · Clin Transplant · 2026-10-01

Meta-analysis of 12 cohort studies (457 recipients) of solid organ donors with multidrug-resistant Gram-negative bacteria: pooled donor-derived infection rate 29%; 40% in high-risk, 0% in low-risk transplants. 90-day mortality 14% overall, 49% with infection.

Meta-analysisn = 457
Paraskevas et al. Risk of Donor-Derived Infections From Organ Donors Colonized or Infected With Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review and Meta-Analysis
Transplantation · Transpl Int · 2026-09-23

In an open-label RCT of 60 kidney transplant recipients (of 100 planned) with late active AMR and de novo DSA, adding bortezomib to standard care did not improve the 12-month composite endpoint (40.0% vs 33.3%; p=0.59) and raised serious adverse events (76.7% vs 46.7%).

RCTn = 60
Snanoudj et al. Bortezomib in combination with standard-of-care for late active antibody-mediated rejection with de novo donor-specific antibodies after kidney transplantation: a multicenter randomized trial
Transplantation · Clin Transplant · 2026-06-01

Secondary analysis of the cluster-randomised DONORS trial (1043 brain-dead potential donors): baseline lactate ≥2 mmol/L was associated with more cardiac arrest before procurement (13.7% vs 9.4%; adjusted OR 1.59) and fewer actual donors (39.1% vs 46.9%).

Secondary analysisn = 1,043
Westphal et al. Lactate and Lactate Clearance as Outcome Predictors in Brain-Dead Potential Organs: A Secondary Cohort Analysis Embedded Within a Cluster-Randomized Clinical Trial
Transplantation · Am J Transplant · 2026-05-22

In 31 adult transplant recipients (30 solid organ) with norovirus, nitazoxanide did not shorten median time to symptom resolution vs placebo (19.0 vs 11.0 days; P=.459) or time to negative stool PCR; no serious drug-related adverse events.

RCTn = 31
Boutin et al. A phase 2 multicenter, prospective, randomized, double-blind study to assess the clinical and antiviral efficacy and safety of nitazoxanide for the treatment of norovirus in hematopoietic stem cell and solid organ transplant recipients
Transplantation · Am J Transplant · 2026-05-21

In 70 high-CMV-risk kidney transplant recipients, maribavir 400 mg twice daily vs valganciclovir 900 mg daily prophylaxis showed no significant difference in clinically significant leukopenia (22.9% vs 5.7%, P=.084); valganciclovir had more days with low white cell counts.

RCTn = 70
Taber et al. Single-center, open-label, randomized controlled trial comparing the tolerability of maribavir 400 mg twice daily versus standard-dose valganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.